RT Journal Article
SR Electronic
T1 Mass screening of asymptomatic persons for SARS-CoV-2 using saliva
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.13.20174078
DO 10.1101/2020.08.13.20174078
A1 Yokota, Isao
A1 Shane, Peter Y
A1 Okada, Kazufumi
A1 Unoki, Yoko
A1 Yang, Yichi
A1 Inao, Tasuku
A1 Sakamaki, Kentaro
A1 Iwasaki, Sumio
A1 Hayasaka, Kasumi
A1 Sugita, Junichi
A1 Nishida, Mutsumi
A1 Fujisawa, Shinichi
A1 Teshima, Takanori
YR 2020
UL http://medrxiv.org/content/early/2020/08/15/2020.08.13.20174078.abstract
AB Background COVID-19 has rapidly evolved to become a global pandemic due largely to the transmission of its causative virus through asymptomatic carriers. Detection of SARS-CoV-2 in asymptomatic people is an urgent priority for the prevention and containment of disease outbreaks in communities. However, few data are available in asymptomatic persons regarding the accuracy of PCR testing. Additionally, although self-collected saliva has significant logistical advantages in mass screening, its utility as an alternative specimen in asymptomatic persons is yet to be determined.Methods We conducted a mass-screening study to compare the utility of nucleic acid amplification, such as reverse transcriptase polymerase chain reaction (RT-PCR) testing, using NPS and saliva samples from each individual in two cohorts of asymptomatic persons: the contact tracing cohort and the airport quarantine cohort.Results In this mass-screening study including 1,924 individuals, the sensitivity of nucleic acid amplification testing with nasopharyngeal and saliva specimens were 86% (90%CI:77-93%) and 92% (90%CI:83-97%), respectively, with specificities greater than 99.9%. The true concordance probability between the nasopharyngeal and saliva tests was estimated at 0.998 (90%CI:0.996-0.999) on the estimated airport prevalence, 0.3%. In positive individuals, viral load was highly correlated between NPS and saliva.Conclusion Both nasopharyngeal and saliva specimens had high sensitivity and specificity. Self-collected saliva is a valuable specimen to detect SARS-CoV-2 in mass screening of asymptomatic persons.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Health, Labour and Welfare Policy Research Grants 20HA2002.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Ethics Board (Hokkaido University Hospital Division of Clinical Research Administration Number: 020-0116).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are not publicly available due to unaccepted work on any peer-reviewed journal but will be published after acceptance of peer-reviewed journal.